Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
Tài liệu tham khảo
Smith, 2001, J Am Coll Cardiol, 37, 2239i, 10.1016/S0735-1097(01)01345-6
Popma, 2001, Antiplatelet therapy in patients undergoing percutaneous coronary intervention, Chest, 119, 321S, 10.1378/chest.119.1_suppl.321S
Schwartz, 1988, Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty, N Engl J Med, 318, 1714, 10.1056/NEJM198806303182603
Barnathan, 1987, Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty, Circulation, 76, 125, 10.1161/01.CIR.76.1.125
Kong, 1998, Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease, Circulation, 98, 2829, 10.1161/01.CIR.98.25.2829
Fuster, 1992, The pathogenesis of coronary artery disease and the acute coronary syndromes, N Engl J Med, 326, 242, 10.1056/NEJM199201233260406
Topol, 1998, Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence, Circulation, 97, 211, 10.1161/01.CIR.97.2.211
Van Langenhove, 2000, Distal embolization: a threat to the coronary artery?, Circulation, 102, E95, 10.1161/01.CIR.102.13.e95
Webb, 1999, Retrieval and analysis of particulate debris after saphenous vein graft intervention, J Am Coll Cardiol, 34, 468, 10.1016/S0735-1097(99)00196-5
Savage, 1995, Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II), Circulation, 92, 3194, 10.1161/01.CIR.92.11.3194
van Domburg, 2001, Long-term clinical outcome after coronary balloon angioplasty: identification of a population at low risk of recurrent events during 17 years of follow-up, Eur Heart J, 22, 934, 10.1053/euhj.2000.2420
O'Neill, 2000, Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: Evaluation of Oral Xemilofiban in Controlling Thrombotic Events, N Engl J Med, 342, 1316, 10.1056/NEJM200005043421803
Hannan, 2000, A comparison of short- and long-term outcomes for balloon angioplasty and coronary stent placement, J Am Coll Cardiol, 36, 395, 10.1016/S0735-1097(00)00752-X
2000, Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial, Lancet, 356, 2037, 10.1016/S0140-6736(00)03400-0
Chew, 2001, Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials, Circulation, 103, 201, 10.1161/01.CIR.103.2.201
Bossavy, 1998, A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans, Blood, 92, 1518, 10.1182/blood.V92.5.1518
Herbert, 1998, The antiaggregating and antithrombotic activity of clopidrogrel is potentiated by aspirin in several experimental models in the rabbit, Thromb Haemost, 80, 512, 10.1055/s-0037-1615238
Moshfegh, 2000, Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy, J Am Coll Cardiol, 36, 699, 10.1016/S0735-1097(00)00817-2
Mehta, 2000, The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programe: rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease, Eur Heart J, 21, 2033, 10.1053/euhj.2000.2474
Rosenbaum, 1991, Discussing hidden bias in observational studies, Ann Intern Med, 115, 901, 10.7326/0003-4819-115-11-901
Joffe, 1999, Propensity scores, Am J Epidemiol, 150, 327, 10.1093/oxfordjournals.aje.a010011
D'Agostino, 1998, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group, Stat Med, 17, 2265, 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
Boersma, 1999, Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention, Circulation, 100, 2045, 10.1161/01.CIR.100.20.2045
Cannon, 2001, Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban, N Engl J Med, 344, 1939, 10.1056/NEJM200106213442501
Wallentin, 2000, Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial, Lancet, 356, 9, 10.1016/S0140-6736(00)02427-2
1994, Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, BMJ, 308, 81, 10.1136/bmj.308.6921.81
ten Berg, 2000, Effect of coumarins started before coronary antioplasty on acute complications and long term follow-up: a randomised trial, Circulation, 102, 386, 10.1161/01.CIR.102.4.386
Sakatani, 1999, Intracoronary surface changes after Palmaz-Schatz stent implantation: serial observations with coronary angioscopy, Am Heart J, 138, 962, 10.1016/S0002-8703(99)70024-4
Grewe, 2000, Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen, J Am Coll Cardiol, 35, 157, 10.1016/S0735-1097(99)00486-6
Topol, 2001, Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary intervention, N Engl J Med, 344, 1888, 10.1056/NEJM200106213442502